From generalized to personalized treatments: the need for precision pharmacotherapy in addiction medicine

Substance and alcohol use disorders (S/AUDs) are chronic, relapsing brain diseases with multifactorial etiologies, arising from complex interactions among genetic, environmental, and biological factors. Despite the availability of evidence-based treatments, clinical management remains challenging due to marked heterogeneity in disease presentation and treatment response. Advances in other medical fields, such as oncology and immunology, have demonstrated the value of biomarkers for patient stratification and personalized interventions. In addiction medicine, however, pharmacological and non-pharmacological treatments are largely generalized, with minimal consideration of individual characteristics, including sex differences. Women with S/AUDs often present with comorbid psychiatric conditions and experience unique pharmacokinetic and pharmacodynamic profiles influenced by hormonal fluctuations, which can affect medication efficacy, safety, and tolerability. Pharmacogenetic studies highlight the role of single nucleotide polymorphisms in drug-metabolizing enzymes, transporters, and receptors in shaping response to opioid and alcohol use disorder therapies. Emerging evidence further supports the potential of neurobiological and genetic markers to guide treatment with conventional medications and novel interventions, including psychedelic-assisted therapies. Collectively, these findings underscore the critical need to integrate precision medicine approaches in addiction treatment. Personalized, biomarker-informed strategies promise to optimize efficacy, reduce adverse effects, and improve patient-centered outcomes, offering a transformative framework for the management of S/AUDs.

Authors

Institutions

Publication Details

Journal
Drug Metabolism and Personalized Therapy
Published
2026-11-16
DOI
https://doi.org/10.1515/dmpt-2026-0004
Primary Topic
Substance Abuse Treatment and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

From generalized to personalized treatments: the need for precision pharmacotherapy in addiction medicine

Maurizio Coppola, Raffaella Mondola
1 links
Drug Metabolism and Personalized Therapy
Substance Abuse Treatment and Outcomes
article

From generalized to personalized treatments: the need for precision pharmacotherapy in addiction medicine

Maurizio Coppola, Raffaella Mondola
article en

Abstract

Substance and alcohol use disorders (S/AUDs) are chronic, relapsing brain diseases with multifactorial etiologies, arising from complex interactions among genetic, environmental, and biological factors. Despite the availability of evidence-based treatments, clinical management remains challenging due to marked heterogeneity in disease presentation and treatment response. Advances in other medical fields, such as oncology and immunology, have demonstrated the value of biomarkers for patient stratification and personalized interventions. In addiction medicine, however, pharmacological and non-pharmacological treatments are largely generalized, with minimal consideration of individual characteristics, including sex differences. Women with S/AUDs often present with comorbid psychiatric conditions and experience unique pharmacokinetic and pharmacodynamic profiles influenced by hormonal fluctuations, which can affect medication efficacy, safety, and tolerability. Pharmacogenetic studies highlight the role of single nucleotide polymorphisms in drug-metabolizing enzymes, transporters, and receptors in shaping response to opioid and alcohol use disorder therapies. Emerging evidence further supports the potential of neurobiological and genetic markers to guide treatment with conventional medications and novel interventions, including psychedelic-assisted therapies. Collectively, these findings underscore the critical need to integrate precision medicine approaches in addiction treatment. Personalized, biomarker-informed strategies promise to optimize efficacy, reduce adverse effects, and improve patient-centered outcomes, offering a transformative framework for the management of S/AUDs.

Drug Metabolism and Personalized Therapy
Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT)
Good health and well-being
Substance Abuse Treatment and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon